Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

BMS cognition enhancer not superior to placebo in clinical study

Jan. 23, 1997

Clinical results of gabapentin in ALS reported

Jan. 23, 1997

Glaxo Wellcome claims new formulation of anxiolytic agent

Jan. 23, 1997

Neurex compound headed for pivotal trials in head trauma

Jan. 23, 1997

5-HT3/5-HT4 receptor ligands disclosed by Synthelabo

Jan. 23, 1997

Serotonergic trophic factors offered for licensing

Jan. 22, 1997

New agents for treating encephalopathies from Takeda

Jan. 22, 1997

New antimigraine drug candidates from Lilly

Jan. 22, 1997

Histamine H3 receptor antagonists in development at Gliatech

Jan. 22, 1997

New market for Mivacron

Jan. 21, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
IMV-101 shows promise for B-cell malignancies
BioWorld Science
IMV-101 is a new CAR T-cell therapy targeting CD19 developed by Suzhou Immunofoco Biotechnology Co. Ltd. for the potential treatment of B-cell malignancies and...